- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05883527
Partnership in Safeguarding People With Dementia From Primary and Social Care Perspectives
"Adult safeguarding is everyone's responsibility". The Care Act 2014 makes safeguarding a legal duty. It provides local authorities and other agencies in England with a responsibility to protect adults with care and support needs from abuse and neglect. This is done most effectively when all relevant agencies work together. This is particularly important for people living with dementia, as they are at higher risk of abuse or neglect. Such abuse is most common in their own homes and care settings. Primary and social care professionals are likely to have regular contacts with older people, hence have opportunities for early identification and prevention of abuse. However, little is known about how primary care practitioners work in partnership with social care and other agencies to investigate and manage abuse.
Aims:
This project will outline how health professionals in primary care settings understand and respond to abuse and what their understandings of safeguarding law and policy are. It will also identify how social services departments assess and manage referrals relating to people living with dementia in primary care settings. Furthermore, the study will analyse the experiences of people with dementia and families who are at the centre of safeguarding
Methods:
This study has three phases. In phase 1, the investigators will synthesise current research and practice evidence to develop a theory of safeguarding conceptualisation and process. In phase 2, the investigators will analyse national statistics on safeguarding (NHS digital dataset), ageing and dementia data (English Longitudinal Study of Ageing) to understand patterns of reporting and how they vary across location, gender, ethnicity and time period. In phase 3, the investigators will interview GPs, social workers, safeguarding leads, independent advocates, people with dementia, family members, support workers, carers and other professionals who make or receive referrals via primary care. As part of phase 3 group discussions will also be conducted, in which professionals will come together to share their experiences, and will identify approaches for preventing abuse and collaboration amongst relevant agencies. Phase 3 will inform the development of complex case studies, drawing on data from phases 1 and 2.
Impact:
This study will help develop practice guidance for professionals, to aid multi-agency collaboration in safeguarding cases specific to dementia. This will be developed in consultation with the PPIE (Patient and Public Involvement and Engagement) members and practitioners. Videos will also be produced and plain English versions of case studies of complex safeguarding scenarios and strategies in consultation with safeguarding leads, law experts, training providers and other key stakeholders. Experts by experience (working with, caring for or living with dementia), will be able to guide the team with cultural nuances and appropriateness to ensure that the material developed is sensitive to all populations. An info graph/pictograph displaying signs of abuse, staying safe and what to do, aimed at people with dementia and family will be compiled. The investigators will liaise with national safeguarding leads so that this information can be displayed in GP clinics. Furthermore, the investigators will contact social responsibility personnel for supermarkets and discuss the potentials of wider circulation for displaying this information in stores.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Katarzyna Szulewska
- Phone Number: 01613067689
- Email: katarzyna.szulewska@manchester.ac.uk
Study Contact Backup
- Name: Reena Lasrado
- Email: reena.lasrado@manchester.ac.uk
Study Locations
-
-
-
Leeds, United Kingdom
- Recruiting
- CRN
-
Contact:
- Emma Oughton
-
Leeds, United Kingdom
- Not yet recruiting
- Leeds Local Authority
-
Contact:
- Annemarie Ulph
-
Manchester, United Kingdom
- Recruiting
- CRN
-
Contact:
- Emma Oughton
-
Manchester, United Kingdom
- Not yet recruiting
- Greater Manchester Local Authority
-
Contact:
- Tina Mallon
-
Southport, United Kingdom
- Recruiting
- CRN
-
Contact:
- Emma Oughton
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Health and social care professionals:
- GPs, Nurses, social workers, mental health professionals, support workers, IMCA (independent mental capacity advocates) and other health care professionals in GP surgeries and integrated social care hubs with experience in facilitating safeguarding.
- Safeguarding lead in GP surgeries, social care organisations and other organisations (advocacy agencies).
- Professionals from third-sector organisations who have previously raised safeguarding concerns regarding adults living with Dementia
Service users and carers/family:
- People with dementia who have been involved in the safeguarding process, with mental capacity to consent.
- Family members of people with dementia who have been previously involved in the safeguarding process
- Individuals who were involved in a safeguarding inquiry in the past, which is NOT ongoing at the time of interview.
Exclusion Criteria:
Health and social care professionals at GP practices, social care organisations and third sector organisations without experiences of safeguarding older adults and unwilling to participate in the study.
- People with dementia who lack capacity to consent.
- Individuals involved in an active and ongoing safeguarding inquiry.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Health and Care Professionals
GP's, nurses, social workers, mental health professionals, support workers, Independent mental capacity advocates (IMCA), and other HCP's working in GP surgeries and integrated social care hubs.
Safeguarding leads in GP surgeries, social care organisations and other relevant organisations.
Professionals from third-sector organisations who have previous experience of safeguarding.
|
Exploring the safeguarding process through interviews and a focus group.
|
|
People Living with Dementia
Who have been involved in the safeguarding process and have capacity to consent.
|
Exploring the safeguarding process through interviews.
|
|
Paid carers of people living with dementia
Who have been involved in the safeguarding process.
|
Exploring the safeguarding process through interviews.
|
|
Family members of people living with dementia
Who have been involved in the safeguarding process.
|
Exploring the safeguarding process through interviews.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trends in reporting of routinely collected safeguarding datasets - NHS digital
Time Frame: September 2022 - March 2024
|
Number of reports of safeguarding concerns and section 42 enquiries in England.
Type of risks, source of risks, location, age, gender, ethnicity, health condition.
|
September 2022 - March 2024
|
|
Trends in reporting of routinely collected safeguarding datasets - ELSA data
Time Frame: data years: 2002-2017
|
The prevalence of dementia across England, number of older people with dementia in receipt of care and who gave the care in each local authority in England.
|
data years: 2002-2017
|
|
Quality Outcomes Framework (QOF) Recorded Dementia Diagnoses
Time Frame: data years: 2021-2022
|
Rate of dementia diagnosis in each local authority district in England and demographic characteristics of those with dementia diagnosis in each NHS CCG in England.
|
data years: 2021-2022
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contexts, Mechanisms and Outcomes (CMO's) from the Rapid Realist Literature Review
Time Frame: September 2022 - March 2024
|
The rapid realist review will investigate how health & social care professionals conceptualise and respond to risks of abuse and neglect involving people with dementia in England, UK.
The review will be informed by Rameses guidelines and aims to develop initial programme theories.
|
September 2022 - March 2024
|
|
Interpretative Phenomenological Analysis (IPA) of Interviews
Time Frame: September 2022 - March 2024
|
IPA of interview transcripts will lead to an in-depth understanding of the lived experiences of safeguarding from the perspective of health and social care professionals, people living with dementia, family caregivers and other relevant professionals.
|
September 2022 - March 2024
|
|
Interpretative Phenomenological analysis (IPA) of Focus Group - with health and care professionals
Time Frame: September 2022 - March 2024
|
Lived experiences of safeguarding from the perspective of various professionals, including what worked, what did not work, understanding of legal thresholds, strategies for prevention and collaboration across agencies.
|
September 2022 - March 2024
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRAS ID: 319897
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
Benjamin Rose Institute on AgingNational Institute on Aging (NIA)RecruitingMild Dementia | Moderate DementiaUnited States
-
Yaolin PeiNational Institutes of Health (NIH)RecruitingEnd of Life Decision Making | Dementia Caregivers | Advanced DementiaUnited States
-
Benuvia Therapeutics Inc.MandaraNot yet recruiting
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityCompletedDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeActive, not recruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityCompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
NYU Langone HealthRecruiting
-
The University of Hong KongNot yet recruiting
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
Clinical Trials on Not applicable as not an intervention - HCP's
-
Joop P.W. van den BerghCompletedFractures, Bone | Physical Activity | Osteoporosis | Patient FallNetherlands
-
Allegro Diagnostics, Corp.Medical University of South Carolina; University of Missouri-Columbia; University... and other collaboratorsCompleted
-
University of OxfordBrigham and Women's Hospital; University College, London; Liverpool Heart and... and other collaboratorsActive, not recruitingAtrial Fibrillation New OnsetUnited Kingdom
-
University of OxfordIntensive Care National Audit & Research CentreActive, not recruitingMyocardial Infarction | Heart Failure | Stroke | Critical Illness | Covid19 | Renal Failure | Deep Vein Thrombosis | Pulmonary EmbolismUnited Kingdom
-
Shanghai Zhongshan HospitalCompleted
-
Assiut UniversityNot yet recruitingPhiladelphia Negative Myeloproliferative Neoplasms
-
Royal Brompton & Harefield NHS Foundation TrustUnknownEvaluation of Speckle Tracking Parameters as Predictors of Successful VA SPECKLE ECMO (SPECKLE-ECMO)Cardiogenic ShockUnited Kingdom
-
MedicineJanssen Pharmaceuticals; National Medical Research Council (NMRC), SingaporeUnknown
-
Centre Hospitalier Universitaire de BesanconCompletedRathke's Cleft CystFrance
-
National University of SingaporeT3 Health PTE LTDNot yet recruitingAging | Obesity & OverweightSingapore